Duke Study Eliminates Treatment Differences As Reason For Higher Prostate Cancer Mortality In Blacks

July 14, 1998

DURHAM, N.C. -- A Duke University Medical Center study debunks suspicions that unequal health care is the root of higher death rates among black prostate cancer patients. The researchers recommend looking to biological differences and later diagnosis to resolve the disparity in survival between black and white patients.

Nationwide, prostate cancer is fatal twice as often for blacks as for whites; in North Carolina, the mortality rate for men is more than two and a half times that of white men, the highest in the country.

In a study reported in the July 15 issue of the journal Cancer, Duke researchers surveyed 231 men (117 black, 114 white) from 63 N.C. counties who had been diagnosed with prostate cancer between 1994 and 1995. The survey was designed to help determine whether a difference in treatment of the disease accounted for the state's high black mortality rate.

Lead author Wendy Demark-Wahnefried, Ph.D., said the study, plus statewide treatment data, effectively ruled out a difference in treatment options as the root of the disparity in mortality rates. Men who participated in the study reported having essentially the same choices for treatment. The phone survey further found that both black and white patients were equally satisfied with their cancer treatment, and that both groups cited their physicians as having the greatest influence on the choice of treatment. The patients' stage of disease largely dictated treatment options, the researchers said, showing adherence to accepted standards of care.

Patients in the study received treatment from one of 16 facilities in North Carolina. Researchers concluded that with one exception, hormonal therapy, black men and white men were offered the same treatment options for their prostate cancer, including surgery, radiation and other therapies, and the option of "watchful waiting," where the patient's disease is monitored, but not actively treated unless it progresses. Black men were offered hormonal therapy less often than white men, though the study did not determine a reason for the difference.

Since black men also are diagnosed at later stages, when the disease is much harder to treat, the researchers are now studying whether there are differences in screening practices among blacks and whites and reasons why black men may not be screened routinely.

"African American men may have different beliefs about prostate cancer," Demark-Wahnefried said. "Although they realize that they may be at increased risk for the disease, they may not personalize that knowledge. They may think they are only at average risk. We need to learn more about why these mortality rates are so high."

She said the researchers also are analyzing data collected from ongoing studies to determine whether genetic and environmental factors play a role in mortality rates among African-American men. They are looking at diet, occupation, lifestyle and family history, among other factors.

The study, funded primarily by the Committee for Urologic Research, Education and Development at Duke and the N.C. Department of Health and Human Services, was the collaborative effort of researchers from Duke, UNC-Chapel Hill and the state of North Carolina.

The 16 health care facilities participating in the study were Carolinas Medical Center in Charlotte; Craven County Hospital in New Bern; Duke and Durham Regional Hospital in Durham; Forsyth Medical Center in Winston-Salem; Greenville Urology; High Point Medical Center; Medical Park Hospital in Winston-Salem; Moses Cone Hospital in Greensboro; Nash General Hospital in Rocky Mount; N.C. Baptist Hospital in Winston-Salem; Presbyterian Hospital in Charlotte; Rex Hospital in Raleigh; UNC Hospitals in Chapel Hill; Wake Medical Center in Raleigh; and Wayne Memorial Hospital in Goldsboro.

Duke University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.